Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AV COVID 19

Next Previous
Drug Profile

AV COVID 19

Alternative Names: anti-SARS-CoV-2 COVID-19 vaccine - Aivita Biomedica; AV-COVID-19; DC-ATA; DCV - Aivita Biomedical; Dendritic cell vaccine - Aivita Biomedical

Latest Information Update: 18 May 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AiVita Biomedical
  • Class COVID-19 vaccines; Dendritic cell vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III COVID 2019 infections

Most Recent Events

  • 03 May 2023 AiVita Biomedical withdraws phase-I/II trial in COVID-2019 infections (Prevention, In adults, In the elderly) in May 2023 (SC) prior to enrolment, due to clinical hold by FDA and never gave an okay to start (NCT04386252)
  • 29 Aug 2022 Immunogenicity and adverse events data from a phase I trial in COVID-2019 infections released by AIVITA Biomedical
  • 29 Aug 2022 Immunogenicity and adverse events data from a phase II trial in COVID-2019 infections released by AIVITA Biomedical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top